Novartis Sues Dr. Reddy's Over ANDA For Cancer Drug
Novartis said in a Delaware federal court complaint that Dr. Reddy's abbreviated new drug application would violate the patent for Gleevec, U.S. Patent Number 6,894,051, issued in 2005.
"Patents are vital to the ability of innovative companies like Novartis to invest in high-risk research. ... We have confidence in the integrity of the Gleevec patent...
To view the full article, register now.